Evaluation of signal strengthening criteria among outcomes where rate ratios were significantly increased
| Criterion | Behcet’s syndrome | Raynaud’s disease | Type 1 diabetes |
|---|---|---|---|
| Analysis based on 20 or more vaccine exposed cases | No (n=5) | Yes (n=37) | Yes (n=99) |
| Rate ratio ≥3.0 | Yes (3.37) | No (1.67) | No (1.29) |
| Significantly increased rate ratios in both countries when analysed separately | No (3.38*, 95% CI 0.83 to 13.84 for Sweden (3 exposed cases); 4.63†, 95% CI 0.64 to 33.66 for Denmark (2 exposed cases)) | No (1.86*, 95% CI 1.19 to 2.89 for Sweden (25 exposed cases); 1.46*, 95% CI 0.64 to 3.33 for Denmark (12 exposed cases)) | No (1.47*, 95% CI 1.08 to 2.01 for Sweden (47 exposed cases); 1.09*, 95% CI 0.76 to 1.57 for Denmark (52 exposed cases)) |
*Adjusted for age in two year intervals, calendar year, and parental country of birth, parental education, and paternal socioeconomic status.
†Adjusted for age in two year intervals (model with full adjustment did not converge).